← Search & browse all drugs
CARDIOVASCULAR SYSTEM › CARDIAC THERAPY › VASODILATORS USED IN CARDIAC DISEASES › Other vasodilators used in cardiac diseases
serelaxin
C01DX21
Forms & Strengths
- Intravenous infusion: 5 mg/mL (development discontinued by Novartis in 2017 following negative Phase 3 trial results)
Adult Dosing
- Acute heart failure: 30 mcg/kg/day administered via continuous intravenous infusion for 48 hours
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
Indications
- Investigated for the treatment of acute heart failure to relieve dyspnea and reduce short-term mortality (clinical development halted)
Mechanism of Action
- Recombinant form of human relaxin-2; binds to the relaxin family peptide receptor 1 (RXFP1), causing vasodilation, reducing systemic vascular resistance, and improving renal blood flow
Contraindications
- Hypersensitivity to serelaxin or any component of the formulation
- Hypotension (systolic blood pressure < 110 mmHg)
Adverse Reactions
- Hypotension
- Headache
- Dizziness
- Injection site reactions
- Elevated serum creatinine
Drug Interactions
- Antihypertensive agents: May potentiate blood pressure-lowering effects, increasing the risk of symptomatic hypotension
Curated Content: Needs Vetting Before Put to Clinical Use